Intradialytic hypotension is a common complication of hemodialysis and can lead to increased morbidity and mortality among patients with end-stage renal disease.
Results showed that patients with a baseline APACHE II scores >30 had a significantly improved 28-day mortality trend in the angiotensin II group vs. the placebo group.
In a clinical trial of 321 patients with shock and a critically low blood pressure, significantly more patients responded to treatment with Giapreza compared to those treated with placebo.
"Newborn screening at birth is crucial to quickly identify infants at risk of hearing loss and congenital heart disease so they can receive early intervention and follow-up care," Brenda Fitzgerald, MD, director of the CDC.
After adjustments, measurement 1 was significantly associated with risk of fall (HR 1.22, 95% CI: 1.03-1.44), fracture (HR 1.16, 95% CI: 1.01-1.34), syncope (HR 1.40, 95% CI: 1.20-1.63), and death (HR 1.36, 95% CI: 1.23-1.51). Measurement 2 was associated with all long-term outcomes, including motor vehicle crashes (HR 1.43, 95% CI: 1.04-1.96).
Researchers randomized patients with vasodilatory shock receiving more than 0.2 µg of norepinephrine/kg body weight/minute or equivalent dose of another vasopressor to receive angiotensin II or placebo infusions.
The researchers found heart rate was controlled within 15 minutes in 87% of patients who received a 70-mg dose of the nasal spray; 75% of patients who got 105-mg; and 95% of patients given a 140-mg dose.
The mean and median pulmonary complications score was 1.8 and 1.7, respectively, for the intensive recruitment strategy group, compared with 2.1 and 2.0, respectively, for the moderate strategy group.
The researchers observed an increased relative risk of UF with impaired orthostatic BP stabilization at 40 seconds after standing (OH) (relative risk, 1.52).
Nipride RTU is approved for immediate blood pressure reduction and also carries a Boxed Warning describing the possibility of excessive hypotension and cyanide toxicity.
La Jolla announced positive data from the ATHOS-3 study which evaluated LJPC-501 (angiotensin II) for the treatment of catecholamine resistant hypotension (CRH).
The FDA has approved updates to all antipsychotic medication labels to specifically warn of somnolence, postural hypotension, and motor and sensory instability risks.
The Food and Drug Administration (FDA) has approved Corphedra (ephedrine sulfate injection; Par) for the treatment of clinically important hypotension occurring in the setting of anesthesia.
There is an association between orthostatic hypotension and an increased risk for dementia, according to a new study published online October 11 in PLOS Medicine.
Hypersensitivity reactions including anaphylaxis, angioedema, bronchospasm, urticaria and rash have been reported in postmarketing experience.
Sandoz announced a voluntary recall of four lots of Phenylephrine HCI Injection, USP, 10mg/mL, 5mL and 10mL vials due to concerns of product sterility during an inspection at Allergy Laboratories, Inc.
In adults with septic shock, early vasopressin use vs. norepinephrine did not improve the number of kidney failure-free days, a study in JAMA concluded.
Use of the norepinephrine oral prodrug, droxidopa, for the treatment of symptomatic neurogenic orthostatic hypotension is effective and "generally well tolerated across a range of ages," including in those 75 years and older.
PharMEDium Services, LLC announced a voluntary recall of 29 lots of 4mg Norepinephrine Bitartrate (16mcg/mL) added to 0.9% Sodium Chloride in 250mL Viaflex Bag and 3 lots of 8mg Norepinephrine Bitartrate (32mcg/mL) added to 0.9% Sodium Chloride in 250mL Viaflex Bag.
In a new study published in Diabetes, researchers examined the effects of hypoglycemia on cardiovascular autonomic control and found that there is a clear change in the body's responses to cardiovascular stress.
An increased risk for violent criminality in males was seen in those with a low resting heart rate in late adolescence, an article published in JAMA has shown.
Resuming treatment with angiotensin receptor blockers (ARBs) within two days following surgery is associated with reduced mortality rates in the first month post-surgery, reports a new study in the journal Anesthesiology.